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Aims To investigate whether genetic variants of the histidine-rich calcium (HRC)-binding protein are associated with idio-
pathic dilated cardiomyopathy (DCM) and its progression.
Methods
and results
We screened 123 idiopathic DCM patients and 96 healthy individuals by single-strand conformation polymorphism
analysis and direct sequencing for genetic variants in HRC. Six polymorphisms were detected: Leu35Leu (A/G),
Ser43Asn (G/A), Ser96Ala (T/G), Glu202_Glu203insGlu (2/GAG), Asp261del (GAT/2), and an in-frame insertion
of 51 amino acids at His321. The analysis of their frequencies did not reveal any signiﬁcant correlation with DCM
development. However, the Ser96Ala polymorphism exhibited a statistically signiﬁcant correlation with the occur-
rence of life-threatening ventricular arrhythmias. During a follow-up of 4.02+2.4 years, the risk for ventricular
arrhythmias was higher (HR, 9.620; 95% CI, 2.183–42.394; P ¼ 0.003) in the Ala/Ala patients, compared with Ser/
Ser homozygous patients. On multivariable Cox regression analysis, the Ser96Ala polymorphism was the only signiﬁ-
cant genetic arrythmogenesis predictor in DCM patients (HR, 4.191; 95% CI, 0.838–20.967; P ¼ 0.018).
Conclusion The Ser96Ala genetic variant of HRC is associated with life-threatening ventricular arrhythmias in idiopathic DCM
and may serve as an independent predictor of susceptibility to arrhythmogenesis in the setting of DCM.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Idiopathic dilated cardiomyopathy (DCM) represents the substrate
for approximately 10% of sudden cardiac deaths (SCDs) in the
adult population.
1 Despite routine use of angiotensin-converting
enzyme (ACE) inhibitors, b-blockers, and spironolactone in
patients with heart failure due to DCM, these patients still have
a considerable annual mortality rate of 5–10%. Sudden
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European Heart Journal (2008) 29, 2514–2525
doi:10.1093/eurheartj/ehn328unexpected death accounts for up to 50% of all deaths and is most
often due to ventricular tachycardia (VT) or ventricular ﬁbrillation
(VF) and less often due to bradyarrhythmias or asystole.
2
A consistent ﬁnding in failing myocardium is altered intracellular
calcium (Ca) handling, manifested by a prolonged time course of
intracellular Ca transients and changes in systolic and diastolic Ca
levels.
3Anincreasingbodyofevidenceindicatesthatabnormalintra-
cellularCahandlingunderliescontractiledysfunction,
4,5andcontrib-
utes to ventricular arrhythmogenesis in failing myocardium.
6,7
Recent studies have shown that histidine-rich calcium (HRC)-
binding protein, a 165 kDa sarcoplasmic reticulum (SR) protein,
mayregulateSRCacyclingduringexcitation–contractioncoupling.
8
Adenoviral-mediatedHRCtransferinprimaryculturedratventricu-
lar myocytes was associated with an increase in SR Ca load, but
decreased Ca release, resulting in depressed myocyte shortening
and relengthening.
9,10 Furthermore, isolated cardiomyocytes from
transgenic mice with HRC overexpression revealed depressed SR
Ca sequestration and delayed Ca decline, as well as relaxation
rates,whichtriggeredhypertrophyduringtheageingprocess.
11Col-
lectively, these ﬁndings suggest that HRC may play a regulatory role
inbothSRCareleaseanduptake.Thus,itcouldbehypothesizedthat
HRC mutations or polymorphisms may affect the SR Ca cycling and
may be associated with depressed cardiac function and remodelling.
In the present study, we screened the HRC gene coding region
in 96 healthy individuals and a well-characterized cohort of 123
non-ischaemic DCM patients, with a long follow-up period.
Although the identiﬁed HRC genetic alterations occur in both
DCM patients and controls with similar frequencies, we demon-
strate that the genetic variant of Ser96Ala in HRC correlates
with ventricular arrhythmogenesis and sudden death in DCM
patients, suggesting that HRC may play a modifying role in the pro-
gression of this disease.
Methods
Patient selection
ThisstudyincludedpatientswithidiopathicDCM,whowerereferredto
theSecond Department ofCardiology,OnassisCardiacSurgery Center
Athens, and the Second Department of Cardiology, Attikon Hospital,
UniversityofAthensfordiagnosisortreatmentofheartfailure,including
implantable cardioverter-deﬁbrillator (ICD) implantation. The patients
were enrolled in the study between June 1999 and December 2005.
The diagnosis of idiopathic DCM was based on the deﬁnition of the
WorldHealthOrganization/InternationalSocietyandFederationofCar-
diologyTaskForce.
12Theexclusioncriteriaincludedthepresenceofsig-
niﬁcant coronary artery stenosis on angiography and non-ischaemic
DCM secondary to valvular heart disease, systemic hypertension,
active myocarditis, and excessive alcohol abuse.
A total of 128 patients, who met the inclusion criteria (see
Supplementary material online, Figure S1), underwent evaluation
including NYHA classiﬁcation, clinical examination, electrocardiogram
(ECG), M-mode, and two-dimensional echocardiography. Ninety-
seven of the enrolled patients had been referred for heart failure diag-
nosis and had complete diagnostic cardiac catheterization, which
revealed DCM. Eighty-nine of them had also endomyocardial biopsy
to rule out myocarditis prior to study entry. The remaining 31 of
the enrolled patients were also referred for heart failure therapy.
These patients had a long history of DCM, diagnosed after coronary
angiography at least 9 months before inclusion in the study, without
any indication of myocarditis. This group included 26 patients, who
were referred for ICD implantation due to prior history of cardiac
arrest (n ¼ 3) or documented sustained VT episodes (n ¼ 23). Five
of the 128 patients initially enrolled did not have complete follow up
data, and were excluded from the analysis.
The study was approved by the institutional review boards of the
Onassis Cardiac Surgery Center and the Attikon Hospital of the Uni-
versity of Athens. All patients provided a written informed consent. An
array of 96 Human Random Control DNA samples (panel 1 out of 5,
Catalogue No.: #06041301), extracted from fresh, single donor blood
samples of healthy Caucasian individuals (37.4+9.7 years of age with
50% females), was obtained from the European Collection of Cell Cul-
tures (ECACC, CAMR, Salisbury, Wiltshire, UK; distributed by
Sigma-Aldrich Ltd, Poole, Dorset, UK). The samples were randomly
selected without any constraints on age or gender. The DNA extrac-
tion, puriﬁcation, and identiﬁcation (determined by short tandem
repeat DNA proﬁling) of these 96 control samples were performed
by ECACC, and it is suitable for a wide range of genetic applications
such as mutation analysis, single-nucleotide polymorphisms genotyping,
and association studies.
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Table 1 Characteristics of patients (n 5 123) upon
study entry and healthy controls (n 5 96)
DCM ECACC
controls
Age at study entry, years 48.6+13.9 37.4+9.7
Sex (female), n (%) 28 (22.8) 48 (50.0)
Clinical characteristics, n (%)
Familial DCM 47 (38.2)
NYHA
Class I 56 (45.5)
Class II 51 (41.5)
Class III 16 (13.0)
Atrial ﬁbrillation (AF) 21 (17.1)
Left bundle branch block (LBBB) 40 (32.5)
LVEF,% 29.3+8.6
LVEDD, mm 67.7+9.3
LVESD, mm 54.9+11.0
ICD (history of sustained VT or VF), n (%) 26 (21.1)
History of unexplained syncope, n (%) 8 (6.5)
Medication at enrolment, n (%)
ACE inhibitor 115 (93.5)
Digitalis 36 (29.3)
Spirinolactone 47 (38.2)
Beta blockers 93 (75.6)
Amiodarone 57 (46.3)
All values are mean+standard deviation.
ECACC, European Collection of Cell Cultures; NYHA, New York Heart
Association classiﬁcation; LVEF, left ventricular ejection fraction; LVEDD, left
ventricular end-diastolic dimension; LVESD, left ventricular end-systolic
dimension; ICD, implantable cardioverter-deﬁbrillator; VT, ventricular tachycardia;
VF, ventricular ﬁbrillation; ACE, angiotensin-converting enzyme.
Effect of Ser96Ala variant in histidine-rich calcium-binding protein on DCM 2515Patient follow-up
After initial evaluation, patients were scheduled for follow-up at 3 and
6 months. Subsequently, patients were evaluated at 6 month intervals
or when device ﬁring occurred for those carrying an ICD. During the
follow up visits, the patients’ clinical status was evaluated in regard to
heart failure symptoms and functional class changes. Echocardiography
was performed in patients with clinical deterioration and 24 h ambulat-
ory ECG was performed in patients who had arrhythmia symptoms.
Device interrogation was performed in patients with ICD. Information
regarding deceased patients was obtained from family members, their
general practitioners, and the hospitals at which they had been
admitted. Particular attention was given to the circumstances of each
death. The endpoints during follow-up were: (i) life-threatening
arrhythmic events, including SCD (deﬁned as death occurring instan-
taneously within 60 min of a change in symptoms or unexpectedly
during sleep), cardiac arrest due to VF (documented by the emergency
service), and episodes of unstable VT (.180 bpm) or VF, which were
terminated after ICD ﬁring, as documented by the electrogram storage
in patients with an ICD; (ii) cardiac death due to pump failure; and (iii)
cardiac transplantation. The endpoints were determined by the clini-
cians involved in the study, who were blinded to the DNA data analy-
sis. Cases were subject to censoring due to: (i) death from non-cardiac
aetiology and (ii) study termination.
Genetic analysis
Total DNA was extracted from venous blood samples, using QIAamp
DNA blood midi kit (Qiagen GmbH, Hilden, Germany). Using Plati-
num Taq DNA polymerase (Invitrogen Corp., Carlsbad, CA, USA),
the HRC coding region, including 2238 bp in the 50 UTR, 20–50 bp
of intronic sequences ﬂanking each exon, and 137 bp downstream
from the stop codon (30 UTR), was ampliﬁed by polymerase chain
reaction (PCR; see Supplementary material online, Table S1). The
PCR products were denatured, rapidly cooled, analysed on MDE poly-
acrylamide gels (Cambrex Bio Science Rockland Inc., Rockland, ME,
USA), and silver stained. For each electrophoresis pattern obtained,
sequencing reactions were performed by Macrogen Inc. (Seoul,
South Korea).
Statistics
Hardy–Weinberg equilibrium was assessed by x
2, likelihood ratio, and
permutation exact test.
13 One-way analysis of variance (ANOVA) for
continuous and x
2 or Fisher’s exact test for categorical variables
were used to compare differences in clinical parameters between
the different genotypes. Multiple logistic regression analysis was used
to estimate the relative risk (RR) of each genetic factor for the pheno-
type under investigation. The Mantel–Cox log-rank test was used to
compare Kaplan–Meier survival curves. Univariable Cox proportional
hazards model was performed to identify the signiﬁcant variables. All
the signiﬁcant variables identiﬁed from univariable analysis, as well as
known factors associated with the outcome, were entered in the mul-
tivariable Cox proportional hazards regression model. Data are pre-
sented as mean+standard deviation. A P-value of ,0.05 was
considered statistically signiﬁcant. Power calculations were performed,
on the basis of frequencies of the rarer allele in the control group. The
sample size in this study would allow detecting an RR (by allele) of 1.6
for any polymorphism with a frequency as rare as 1% in control popu-
lation, and a power of 82.3% at the 0.05 signiﬁcance level (two-sides).
Statistical calculations were carried out by the SigmaStat 3.00 and SPSS
13.0 (SPSS Inc., USA) software.
Figure 1 Intracardiac electrograms showing recording of monomorphic (A) or polymorphic (B) ventricular tachycardia that terminated after
implantable cardioverter-deﬁbrillator ﬁring, from two patients with Ala/Ala at codon 96. Their resting ECGs are also presented (C and D,
respectively).
D.A. Arvanitis et al. 2516Figure 2 Representative example of single strand conformational polymorphism analysis of HRC exon 1 with primer set 7, where the inser-
tion of 51 amino acid residues was found. (A) Single strand conformational polymorphism analysis on 0.5  MDE polyacrylamide gels of three
wild types (lanes 1–3), and one heterozygote for the insertion (lane 4). (B) Same set of DNA products (lanes 1–4) analysed in a 2% agarose gel,
stained with ethidium bromide; M, 100 bp ladder; second to fourth lanes, wild-type samples; ﬁfth lane, heterozygote for the insertion. (C) DNA
sequences: top line, amino acid residues; bottom line, nucleotide sequence. (D) Alignment of the 10 histidine-rich and acidic tandem repeats of
the wild-type histidine-rich calcium. The dashed lines indicate gaps for the best ﬁt of the alignment. (E) Alignment of the histidine-rich and acidic
tandem repeats of the mutant histidine-rich calcium with the 51 amino acids insertion (in bold, highlighted). The dashed lines indicate gaps for
the best ﬁt of the alignment. The in-frame insertion at position 321 adds two extra repeats to the protein.
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Patients and follow-up
A total of 166 patients with non-ischaemic DCM were screened,
and123ofthemwithcompletefollow-updata,whomettheinclusion
criteria as described above, were enrolled in the study. The clinical
characteristics at study entry are presented in Table 1. During
follow-up, an ICD was implanted in another six patients, due to sus-
tained VT episodes. The patients were followed up for a median
period of 4.54 years (interquartile range, 4.92 years; from 1.33 to
6.25 years), and during this period, 28 of them (22.8%) presented
one of the pre-speciﬁed life-threatening arrhythmic events. Speciﬁ-
cally, six out of the 91 patients without ICD (6.6%) died suddenly
and 22 out of the 32 patients with ICD (68.8%) presented haemody-
namicallyunstablemonomorphicVT(n ¼ 20)orpolymorphicVT/VF
(n ¼ 2),documentedbytheelectrogramstorageoftheICD(Figure1).
Interestingly, one of these patients who had presented an episode of
unstable monomorphic VT died suddenly 3 months thereafter. In
addition, seven other patients (5.6%) died due to pump failure and
six (4.9%) underwent heart transplantation during the follow up
period. Finally, two other patients (1.6%) died from a non-cardiac
aetiology.
Genetic analysis for human histidine-rich
calcium genetic variants
Six genetic alterations were identiﬁed in the human HRC coding
region. Three of them were single-nucleotide substitutions. One
was silent for A105G (CTG instead of CTA), which encodes
leucine for codon 35. Two were non-synonymous changes, a
G128A, which affects codon 43 and encodes for asparagine
(AAC) instead of serine (AGC) (Ser43Asn), and a T286G, which
affects codon 96 and encodes for alanine (GCC) instead of
serine (TCC) (Ser96Ala).
An insertion of a triplet 606_607insGAG was also detected in a
minisatellite repeat of eight GAGs, encoding for a stretch of eight
glutamic acid residues (Glu202_Glu203insGlu). In addition, a del-
etion of a triplet 781_783delGAT in a minisatellite repeat of 14
GATs, encoding for a stretch of 14 aspartic acid residues
(Asp261del), was noted. Finally, an in-frame insertion of 153 bp
was identiﬁed (Figure 2A and B) between nucleotides 963 and
964, which encodes 51 additional amino acid residues in HRC
(His321ins51aa). The exact sequence of this insertion and its trans-
lation is depicted in Figure 2C. This polymorphism adds two
histidine-rich acidic tandem repeats to the ten repeats already
present in human HRC (Figure 2D and E). All the identiﬁed HRC
polymorphisms were found to be consistent with the distribution
predicted by the Hardy–Weinberg equilibrium in DCM patients
and controls (see Supplementary material online, Table S2). The
frequencies and the RR of DCM development, associated with
the different HRC polymorphisms observed, did not show any stat-
istical signiﬁcance (Figure 3).
Analysis of histidine-rich calcium variants
in dilated cardiomyopathy patients
Comparison of the evaluated parameters at study entry,
New York Heart Association (NYHA) classiﬁcation, atrial ﬁbrilla-
tion (AF), left bundle branch block (LBBB), left ventricular ejec-
tion fraction (LVEF), left ventricular end-diastolic dimension, left
ventricular end-systolic dimension, ICD (history of sustained VT
Figure 3 Group analysis of the relative risk of dilated cardiomyopathy development associated with each of the histidine-rich calcium geno-
types detected in dilated cardiomyopathy patients and healthy controls. The number of dilated cardiomyopathy cases and controls with a
speciﬁc genotype are presented. Each genotype was compared with the rest, as indicated. None of the differences between polymorphism
frequencies was statistically signiﬁcant.
D.A. Arvanitis et al. 2518or VF prior to study entry), and unexplained syncope, revealed
one statistically signiﬁcant correlation against the identiﬁed HRC
variants. Speciﬁcally, the G allele of the T to G polymorphism
at position 286 (Ser96Ala) correlated well with the history of
sustained VT or VF prior to study entry (patients treated ICD;
x
2 ¼ 11.710, df ¼ 2, P ¼ 0.003; see Supplementary material
online, Table S3; Figure 4). The power of this comparison
was 88.7% at the 0.050 signiﬁcance level. The patients’ clinical
characteristics in relation to Ser96Ala genotype are depicted in
Table 2.
Importantly, the Ala96 (G) allele homozygous DCM patients
were in need of ICD implantation (due to a history of sustained
VT or VF prior to study entry) more frequently than the hetero-
zygotes or the Ser96 (T) homozygotes. The RR for sustained VT
or VF prior to study entry in DCM patients was evaluated in
regard to each HRC polymorphism (Figure 5). Our results indicate
that there was a protective trend for the Ser96Ser homozygous
patients against these arrhythmias, with an RR of 0.124 (95% CI,
0.018–0.870; P ¼ 0.005), compared with Ser96Ala and Ala96Ala
patients. This value is eight times lower than the general risk for
sustained VT or VF prior to study entry of a DCM patient. In con-
trast, the Ala/Ala homozygous patients exhibited an increased risk
of sustained VT or VF (2.356; 95% CI, 1.321–4.203; P ¼ 0.006)
compared with Ser/Ser and Ser/Ala patients. The two DCM
patient populations with and without ICD (history of sustained
VT or VF) are in Hardy–Weinberg equilibrium (x
2 ¼ 1.236,
...............................................................................................................................................................................
...............................................................................................................................................................................
...............................................................................................................................................................................
...............................................................................................................................................................................
Table 2 Clinical characteristics of patients upon study entry in relation to histidine-rich calcium genotype
Ser/Ser (n 5 31) Ser/Ala (n 5 61) Ala/Ala (n 5 31)
Age at study entry, years 42.5+14.0 51.5+11.8 48.9+16.1
Sex, male/female 6 (19.4) 13 (21.3) 9 (29.0)
Clinical characteristics, n (%)
Familial DCM 11 (35.5) 24 (39.3) 12 (38.7)
NYHA
Class I 15 (48.4) 27 (44.3) 14 (45.2)
Class II 13 (41.9) 24 (39.3) 14 (45.2)
Class III 3 (9.7) 10 (16.4) 3 (9.7)
AF 5 (16.1) 9 (14.8) 7 (22.6)
Left bundle branch block (LBBB) 7 (22.6) 23 (37.7) 10 (32.3)
LVEF (%) 29.6+10.4 27.2+9.6 30.2+8.5
LVEDD (mm) 63.0+15.3 65.6+17.5 65.5+14.8
LVESD (mm) 52.0+13.9 52.1+18.2 52.7+13.6
ICD (history of sustained VT or VF), n (%) 1 (3.2) 13 (21.3) 12 (38.7)
History of unexplained syncope, n (%) 4 (12.9) 2 (3.3) 2 (6.5)
Medication usage at enrolment, n (%)
ACE inhibitor 27 (87.1) 55 (90.2) 25 (80.6)
Digitalis 7 (22.6) 19 (31.1) 9 (29.0)
Spirinolactone 15 (48.4) 20 (32.8) 12 (38.7)
Beta blockers 23 (74.2) 43 (70.5) 27 (87.1)
Amiodarone 15 (48.4) 30 (49.2) 12 (38.7)
All values are mean+standard deviation.
NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension; ICD,
implantable cardioverter-deﬁbrillator; VT, ventricular tachycardia; VF, ventricular ﬁbrillation; ACE, angiotensin-converting enzyme.
Figure 4 The histidine-rich calcium polymorphism at position
96 is associated with the history of sustained ventricular tachycar-
dia or ventricular ﬁbrillation of dilated cardiomyopathy patients
prior to study entry. Percentages of dilated cardiomyopathy
patients with Ser/Ser, Ser/Ala, and Ala/Ala at codon 96 in need
of implantable cardioverter-deﬁbrillator implantation during
study entry (*, x
2 ¼ 11.710, df ¼ 2, P ¼ 0.003).
Effect of Ser96Ala variant in histidine-rich calcium-binding protein on DCM 2519df ¼ 2, P ¼ 0.539 and x
2 ¼ 0.0006, df ¼ 2, P ¼ 1.000, respect-
ively). Therefore, the Ser96Ala mode of inheritance for the Ala
allele was evaluated,
14 with respect to the history of sustained
VT or VF, as dominant (RR, 8.424; 95% CI, 1.190–59.619; P ¼
0.005), recessive (RR, 2.544; 95% CI, 1.322–4.896; P ¼ 0.006), or
multiplicative (RR for Ala/Ala, 6.086, and RR for Ala/Ser, 2.467
against Ser/Ser; 95% CI, 1.1936–14.0; x
2 ¼ 11.80; df ¼ 1; P ,
0.001). Multiple logistic regression analysis revealed that the corre-
lation between the Ala96Ala homozygosity and the need of ICD
implantation (history of sustained VT or VF) in DCM patients is
independent from other clinical characteristics (Table 3).
During follow-up, with the exception of a history of sustained
VT or VF prior to study entry, none of the other clinical character-
istics correlated with a life-threatening arrhythmic event, based on
Kaplan–Meier event-free plots (see Supplementary material
online, Figure S2). However, the Kaplan–Meier survival curves
for life-threatening arrhythmic events (Figure 6A) and for cardiac
death from any cause, including life-threatening arrhythmic
events, pump failure, and transplantation (Figure 6B), showed that
the Ala/Ala patients were more susceptible to malignant ventricu-
lar arrhythmias than the Ser/Ala or Ser/Ser patients at HRC codon
96 (Madel–Cox log-rank test, P ¼ 0.005 and ,0.001, for life-
threatening arrhythmic events; and P ¼ 0.038 and 0.017, for
cardiac death from any cause, respectively). All the genetic variants
identiﬁed in this study (Ser43Asn, Ser96Ala, Glu202_Glu203ins-
Glu, and Asp261del) and patients’ characteristics were included
in the univariable Cox proportional hazards models, with the
Figure 5 Relative risk of dilated cardiomyopathy patients for implantable cardioverter-deﬁbrillator implantation (history of sustained ventri-
cular tachycardia or ventricular ﬁbrillation prior to study entry) with respect to histidine-rich calcium polymorphisms. The numbers of dilated
cardiomyopathy patients with and without an implantable cardioverter-deﬁbrillator, respectively, with a speciﬁc genotype are presented. Each
genotype was compared with the rest as indicated. Asterisks indicate statistically signiﬁcant difference. Homozygosity for alanine of the
histidine-rich calcium Ser96Ala polymorphism was associated with an increased risk for malignant ventricular arrhythmias in dilated cardiomyo-
pathy patients prior to study entry, while homozygosity for serine was protective.
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Table 3 Multiple logistic regression analysis of dilated
cardiomyopathy patients clinical characteristics and
genotypetoimplantablecardioverter-deﬁbrillator(history
of ventricular tachycardia or ventricular ﬁbrillation) prior
to study entry (x
2 5 25.098; df 5 10; P 5 0.005)
Variable ICD (history of VT or VF)
OR 95% CI P-value
Genetic variant
Ser96Ala (T!G)
T/G compared with T/T 6.166 0.714–53.228 0.098
G/G compared with T/T 18.213 1.974–168.073 0.010
Clinical characteristics
Age 1.061 1.014–1.110 0.010
Sex 1.504 0.422–5.359 0.529
Familial DCM 0.394 0.133–1.166 0.093
NYHA
Class I compare with III 1.946 0.335–11.299 0.458
Class II compare with III 1.530 0.298–7.863 0.610
AF 0.630 0.164–2.421 0.501
LBBB 0.439 0.136–1.415 0.168
LVEF 0.963 0.890–1.041 0.338
ICD, implantable cardioverter-deﬁbrillator; NYHA, New York Heart Association;
AF, atrial ﬁbrillation; LBBB, left bundle branch block; LVEF, left ventricular ejection
fraction; OR, odds ratio; CI, conﬁdence interval; df, degrees of freedom; with bold
statistical signiﬁcant associations.
D.A. Arvanitis et al. 2520exception of Leu35Leu, which results in a synonymous codon, and
His321ins51aa, that has a low frequency (Table 4). The unadjusted
hazard ratio (HR) for life-threatening ventricular arrhythmias was
9.620 (95% CI, 2.183–42.394; P ¼ 0.003), and for cardiac death
from any cause was 2.719 (95% CI, 1.103–6.704; P ¼ 0.030;
Table 4) for the Ala/Ala, compared with Ser/Ser genotypes. Fur-
thermore, the Ala/Ala genotype was identiﬁed as an independent
factor for prediction of life-threatening ventricular arrhythmias,
with an HR of 4.191 (95% CI, 0.838–20.967; P ¼ 0.018; Table 5),
compared with Ser/Ser, using the multivariable Cox proportional
hazards regression model and controlling for history of sustained
VT or VF prior to study entry and known predictors of the
outcome, namely patient’s age, sex, NYHA classiﬁcation, LBBB,
and LVEF, during the study entry.
Discussion
We identiﬁed herein the ﬁrst genetic variant of an SR Ca-cycling
gene associated with malignant arrhythmias in DCM. The variant
encodes for the Ser96Ala polymorphism in the human HRC and
appears to be a powerful predictor for the occurrence of ventricu-
lar arrhythmias and sudden death in DCM patients. Although new
therapeutic advances have improved survival, the occurrence of
sudden arrhythmogenesis continues to constitute one of the
leading causes of death in DCM. Various approaches for predicting
the risk of SCD have been suggested, but they all yielded limited
insights into the identiﬁcation of positive predictor factors in fatal
arrhythmias.
15 To date, left ventricular dysfunction (LVEF, ,30%)
serves as the only independent predictor for major arrhythmic
Figure 6 Kaplan–Meier plots for the probability of survival from: (A) life-threatening ventricular arrhythmic events including sudden cardiac
death and episodes of unstable VT (.180 b.p.m.) or ventricular ﬁbrillation, which were recorded by an implantable cardioverter-deﬁbrillator
device and (B) cardiac death from any cause, including pump failure, transplantation, sudden cardiac death, and episodes of unstable VT
(.180 b.p.m.) or ventricular ﬁbrillation, which were recorded by an implantable cardioverter-deﬁbrillator device. Each event is depicted as
a step down. Each censored case [due to (A) death from other causes except sudden cardiac death, heart transplantation, and study termination
and (B) death from non-cardiac aetiology and study termination] is marked with a cross. The table at the bottom of the plots indicates the
number of dilated cardiomyopathy patients in risk for each year of the follow-up study. The Ala/Ala homozygotes for the Ser96Ala polymorph-
ism were statistically more susceptible to ventricular arrhythmic events, compared with Ser/Ala heterozygotes and Ser/Ser homozygotes.
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Table 4 Univariable Cox proportional hazards model of time to life-threatening ventricular arrhythmic events or cardiac death from any cause
a
Variable Life-threatening arrhythmic events Cardiac death from any cause
HR 95% CI P-value HR 95% CI P-value
Genetic variant
Ser96Ala (T!G)
T/G compared with T/T 3.281 0.734–14.660 0.120 1.319 0.551–3.155 0.534
G/G compared with T/T 9.620 2.183–42.394 0.003 2.719 1.103–6.704 0.030
Ser43Asn (G!A)
G/A compared with G/G 0.412 0.159–1.069 0.068 0.382 0.167–0.871 0.052
A/A compared with G/G 1.230 0.474–3.191 0.671 0.966 0.394–2.370 0.940
Glu202_Glu203insGlu (2!GAG)
2/GAG compared with 2/2 7.192 1.553–33.317 0.062 3.637 1.119–11.824 0.078
GAG/GAG compared with 2/2 4.098 0.931–18.035 0.076 2.589 0.875–7.656 0.086
Asp261del (GAT!2)
GAT/2 compared with GAT/GAT 1.183 0.346–4.043 0.788 0.606 0.234–1.571 0.302
2/2 compared with GAT/GAT 1.949 0.642–5.923 0.239 0.888 0.384–2.054 0.782
Clinical characteristics
Age 1.058 1.023–1.094 0.001 1.026 1.001–1.051 0.041
Sex 1.104 0.469–2.597 0.821 1.209 0.606–2.414 0.590
Familial DCM 0.683 0.301–1.552 0.363 0.732 0.373–1.436 0.364
NYHA
Class I compare with III 0.388 0.130–1.163 0.091 0.192 0.084–0.442 <0.001
Class II compare with III 0.730 0.263–2.031 0.547 0.389 0.183–0.829 0.014
AF 1.030 0.357–2.970 0.957 1.311 0.580–2.961 0.515
LBBB 1.298 0.608–2.771 0.500 1.263 0.674–2.367 0.465
LVEF 0.973 0.929–1.018 0.230 0.962 0.925–1.000 0.051
ICD (history of sustained VT or VF) 12.266 5.496–27.373 <0.001 5.558 2.986–10.346 <0.001
aCardiac death from any cause, including death due to pump failure, transplantation, sudden cardiac death, and episodes of unstable VT (.180 b.p.m.) or VF, which were recorded by an ICD device.
AF, atrial ﬁbrillation; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; ICD, implantable cardioverter-deﬁbrillator; HR, hazard ratio; CI, conﬁdence interval; df, degrees of freedom; with bold statistical signiﬁcant
associations.
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2events, as revealed by multivariable analysis in one of the best con-
trolled studies for arrhythmia risk stratiﬁcation and primary pre-
vention of sudden death in DCM.
16 However, depressed left
ventricular dysfunction does not appear to be an effective predic-
tor, as it has failed to identify or has presented low accuracy in the
identiﬁcation of patients, that would beneﬁt from implanted cardio-
verter deﬁbrillation (ICD) therapy.
17,18 Thus, efforts to identify
new predictive factors for mortality and especially sudden death
in DCM are very important, since these may hold promise for
effective therapy in individual patients.
Recently, abnormalities in intracellular calcium handling have
been implicated in ventricular arrhythmogenesis of the failing myo-
cardium.
6,7 The impaired calcium handling has been found to pre-
dispose to delayed afterdepolarizations and triggered activity of
arrhythmogenesis, which are considered as main mechanisms,
underlying ventricular arrhythmias in DCM patients. Genetic
studies have also begun to reveal the role of defective myocardial
calcium handling in the pathogenesis of various inherited arrhythmic
syndromes. Support for this notion has been provided by the identi-
ﬁcation of human mutations in the ryanodine receptor 2
19–21 and
calsequestrin (CSQ)
22 genes, which implicated them as the SR
Ca-handling candidates underlying catecholaminergic/polymorphic
VT and arrhythmogenetic right ventricular cardiomyopathy.
Another SR Ca-handling protein, which has been recently
shown to play a role in myocardial calcium handling, is HRC.
8
Increases in HRC levels are associated with impaired SR Ca
uptake and depressed heart contractility, leading to cardiac remo-
delling upon ageing.
9–11To assess whether genetic variants in HRC
may be associated with human DCM, we sequenced the HRC
coding region in a well-characterized DCM group. Five out of six
of the identiﬁed HRC variants, Leu35Leu, Ser43Asn, Ser96Ala,
Glu202_Glu203insGlu, and Asp261del, were described pre-
viously,
23,24 while the 51 amino acid insertion at codon 321 is
reported for the ﬁrst time. Each genetic variant exhibited similar
frequency in controls and DCM patients. However, the Ser96Ala
HRC polymorphism appeared to signiﬁcantly correlate with malig-
nant ventricular arrhythmias or SCDs only in DCM patients.
Speciﬁcally, the Ala/Ala variant was associated with a four-fold
increased risk compared with Ser/Ser variant. Although the func-
tional signiﬁcance of the Ser96Ala variant is not known, bioin-
formatical analysis of the HRC amino acid sequence, using
the NetPhos 2.0
25 and NetPhosK 1.0
25,26 servers, revealed that
Ser96 may be phosphorylated by casein kinase II (prediction
score, 0.972). Indeed, previous studies showed that HRC could
be phosphorylated by casein kinase II in cardiac SR,
27,28 similar
to CSQ.
29 Interestingly, dephosphorylation of CSQ enhances the
RyR channel opening probability and thus, SR Ca release.
30 Consid-
ering the similarities between HRC and CSQ,
8 it is possible that
the lack of the HRC phosphorylation site (Ser96Ala) may also
impair the regulatory effects of HRC on RyR or SERCA2 func-
tion
10,31 and initiate delayed afterdepolarization and ventricular
arrhythmogenesis. Furthermore, since the interaction of HRC to
triadin has been shown to be modulated by Ca,
8,31 reduced SR
Ca levels in DCM would be expected to diminish this complex.
Thus, triadin may be free to interact and modulate RyR activity.
The increased triadin/RyR interaction, which may be further
enhanced by the Ser96Ala HRC variant, coupled with destabiliza-
tion of RyR, may exacerbate spontaneous Ca release and
delayed afterdepolarization initiation leading to lethal arrhythmias
in DCM. The delayed afterdepolarization as a possible mechanism
........................................................ .......................................................
........................................................ .......................................................
...............................................................................................................................................................................
...............................................................................................................................................................................
Table 5 Multivariable Cox proportional hazards model of time to life-threatening ventricular arrhythmic events or
cardiac death from any cause
a
Overall model ﬁt Life-threatening arrhythmic events Cardiac death from any cause
(x
2 5 69.621; df 5 9; P < 0.001) (x
2 5 61.420; df 5 9; P < 0.001)
Variable HR 95% CI P-value HR 95% CI P-value
Genetic variant
Ser96Ala (T!G)
T/G compared with T/T 1.293 0.264–6.344 0.751 0.856 0.314–2.334 0.761
G/G compared with T/T 4.191 0.838–20.967 0.018 2.041 0.688–6.054 0.199
Clinical characteristics
Age 1.027 0.989–1.067 0.170 1.004 0.972–1.036 0.819
Sex 0.854 0.296–2.466 0.770 0.862 0.366–2.026 0.733
NYHA
Class I compare with III 0.743 0.208–2.659 0.648 0.213 0.077–0.590 0.003
Class II compare with III 0.840 0.284–2.483 0.7536 0.354 0.159–0.789 0.011
LBBB 0.762 0.323–1.797 0.535 0.734 0.353–1.527 0.734
LVEF 0.955 0.894–1.020 0.174 0.965 0.914–1.018 0.194
ICD (history of sustained VT or VF) 7.770 3.201–18.856 <0.001 5.364 2.533–11.358 <0.001
aCardiac death from any cause, includes death due to pump failure, transplantation, sudden cardiac death, and episodes of unstable VT (.180 b.p.m.) or VF, which were recorded
by an ICD device.
AF, atrial ﬁbrillation; LBBB, left bundle branch block; ICD, implantable cardioverter-deﬁbrillator; HR, hazard ratio; CI, conﬁdence interval; df, degrees of freedom; with bold
statistical signiﬁcant associations.
Effect of Ser96Ala variant in histidine-rich calcium-binding protein on DCM 2523for ventricular arrhythmia is also supported from stored electro-
gram data, which revealed that nine out of 12 (85%) Ala/Ala
homozygous patients with ventricular arrhythmias exhibited the
ﬁrst beat of tachycardia late in the cardiac cycle.
32
Nevertheless, the current study is subject to several potential
limitations, such as (i) the small sample size, which may limit identi-
ﬁcation of rare mutations; (ii) the calculation of correlations of
genotypes with clinical parameters, which may not reﬂect the
sole risk estimate for disease development and progression;
other parameters, such as patients’ environment, diet, life-style,
and geography may also be involved; (iii) the sensitivity of the
single-strand conformational polymorphism–PCR (SSCP–PCR)
method for mutation screening may limit the identiﬁcation of
certain human mutations;
33 and (iv) the inclusion of DCM patients
with a history of life-threatening ventricular arrhythmias in the
follow up study.
In conclusion, we report here six genetic variants of the human
HRC gene. Importantly, the homozygosity for Ala at amino acid
position 96 was associated with sustained VT in DCM patients.
This is the ﬁrst report of a human HRC polymorphism, which
correlates with life-threatening ventricular arrhythmic episodes in
non-ischaemic DCM patients. Future studies may elucidate the
functional signiﬁcance of the Ser96 Ala genetic variant in DCM.
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Ebstein anomaly and hypertrophic cardiomyopathy
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An asymptomatic 72-year-
old man without cardiovas-
cular risk factors was
evaluated due to a systolic
murmur on an examination.
Transthoracic echocardio-
gram revealed severe left
ventricular hypertrophy
associated with Ebstein
anomaly (Panel A). An asym-
metric septal hypertrophy
was observed (thickness ¼
22 mm). Left ventricular
cavity was reduced (Panel
B). A peak gradient of
40 mmHg was obtained in
the left ventricular outﬂow
tract (Panel C). The tricus-
pid valve insertion was very distal, close to the apex, with almost complete atrialization of the right ventricle with the exception
of a small infundibular component. However, tricuspid regurgitation was no more than moderate. Calculated pulmonary artery systolic
pressure was 40 mmHg. Right chambers were not enlarged. A cardiac magnetic resonance was performed conﬁrming the ﬁndings
(Panels D and E). It showed apical displacement of the hinge point of the septal and posterior leaﬂet from the atrioventricular
ring. Ebstein anomaly was type B, with a large atrialized component of the right ventricle, but the anterior leaﬂet moves freely
(Panel F). The patient had no previous history of supraventricular tachycardias, and familial screening was negative.
Ebstein anomaly is a rare condition (1–5 per 200 000 live births and ,1% of all congenital heart defects). It often associates with
left heart abnormalities involving the myocardium or valves. The most common ﬁnding is a myocardial anomaly resembling mild non-
compaction, but the uncommon is the presence of hypertrophic cardiomyopathy.
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org.
Effect of Ser96Ala variant in histidine-rich calcium-binding protein on DCM 2525